A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma - Concepedia

Concepedia

Publication | Open Access

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

DOI Full Paper Access

112

Citations

42

References

2022

Year

Wu‐tong Ju, Ronghui Xia, Dongwang Zhu, Shengjin Dou, Guopei Zhu, Minjun Dong, Lizhen Wang, Qi Sun, Tongchao Zhao, Zhihang Zhou,

Nature Communications

References

	Year	Citations

Page 1